5439602026-04-012026-06-305439602026-04-012026-06-30in-capmkt:OtherExpenses1Member5439602026-04-012026-06-30in-capmkt:OtherExpenses2Member5439602026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15439602026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25439602026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss35439602026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss45439602026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares543960CONCORDBIONAINE338H01029CONCORD BIOTECH LIMITEDMain BoardEquity2026-04-012027-03-312026-07-312026-07-28INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2026-07-3115:30:002026-07-3116:35:00Declaration of unmodified opinionfalsefalseNotes to the statement of unaudited standalone financial results for the quarter ended June 30 2026 <br /> <br /> 2026-04-012026-06-30UnauditedStandalone26051710001309640002736135000698545000112596000-2547180004118150001500001804730007651780001914039000822096000082209600020365900065000002101590000611937000000061193700017052700078246400010461600015.855.85005.855.85Notes to the statement of unaudited standalone financial results for the quarter ended June 30 2026 <br /> <br /> 1 The above standalone financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on July 31 2026. The Statutory Auditors of the holding company have carried out a limited review of the said results. <br /> <br /> 2 The figures for the quarter ended March 31 2026 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended December 31, 2025 which were subjected to limited review <br /> <br /> 3 On November 21 2025 the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour and Employment has issued draft Central Rules and FAQs to facilitate assessment of the financial impact arising from these changes. Based on managements assessment including actuarial valuation, considering the best information available and ICAI guidance, the company has recognized an incremental liability of Rs 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory driven and non recurring in nature, the impact of the same has been disclosed under exceptional items in the consolidated results for the year ended March 31 2026. The company continues to monitor further clarifications or FAQ from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. <br /> <br /> 4. The company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 Operating Segment <br /> <br /> 5 The above standalone financial results has been prepared in accordance with Indian Accounting Standards Ind AS notified under Section 133 of the Companies Act 2013 read together with Companies Indian Accounting Standards Rules 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India SEBI. <br /> <br /> 6 Celliimune Biotech Private Limited that was incorporated on January 15 2025 has been acquired by Concord Biotech Limited as on April 02 2026. Accordingly Celliimune Biotech Private Limited is a wholly owned subsidiary from April 02 2026.Power and Fuel347201000Others417977000Re-measurement gain/ (loss) on defined benefit plans7156000Income tax relating to re-measurement gain/ (loss) on defined benefit plans-1801000Fair value changes on equity investments through OCI192733000Income tax relating to fair value changes on equity investments through OCI-2756100017052700000170527000UnauditedtrueB S R & Co. LLPtrue2028-07-31